About This Webinar
To date, most FDA-approved biosimilars in the US that are available to patients are primarily administered in a hospital or physician clinic and billed under the medical benefit. But in 2021, we saw the first interchangeable biosimilar insulin approved for patient self-administration, making way for the next wave of pharmacy benefit biosimilars, especially in newer disease areas such as immunology. Self-administered products are primarily billed under the pharmacy benefit, giving PBMs and payers more power to choose what medicines are included on formularies. These medicines will also have a significant impact for patients with inflammatory diseases by providing greater access to treatment options at the pharmacy.
The panel will discuss how the introduction of self-administered biosimilars can impact the inflammatory disease space by providing patients more-affordable, quality treatment options. Speakers will also provide a regulatory background on biosimilar and interchangeable products, discuss how biosimilars promote competition and health system savings and talk about the benefits they can bring to patients and health insurance providers by lowering costs. Speakers will also walk through actionable steps payers can take to promote greater adoption of these biosimilars by ensuring their coverage on formularies.
Attendees Will Learn About
- Updates from the FDA on biosimilar and interchangeable products
- Interchangeability and substitution
- Provider experience with biosimilars
- The current and future state of biosimilar adoption and coverage in the US